Bryan Lawlis, Ph.D., joined our Board in June 2007. From August 2011 to September 2017 he served as the President and Chief Executive Officer of Itero Biopharmaceuticals, LLC, a private holding company that held the assets of Itero Biopharmaceuticals, Inc., a private biotechnology company. Dr. Lawlis co-founded and served as President and Chief Executive Officer of Itero Biopharmaceuticals, Inc. from 2006 until it discontinued operations in August 2011. Dr. Lawlis served as President and Chief Executive Officer of Aradigm Corporation, a pharmaceutical company, from August 2004 to August 2006, and served on its board from February 2005 to August 2006, continuing in both capacities until August 2006. Dr. Lawlis previously served as Aradigm’s President and Chief Operating Officer from June 2003 to August 2004 and its Chief Operating Officer from November 2001 to June 2003. Prior to his time at Aradigm, Dr. Lawlis co-founded Covance Biotechnology Services, a contract biopharmaceutical manufacturing operation, and served as its President and Chief Executive Officer from 1996 to 1999, and as its Chairman from 1999 to 2001, when it was sold to Diosynth RTP, Inc., a division of Akzo Nobel, NV. From 1981 to 1996, Dr. Lawlis was employed at Genencor, Inc., a biotechnology company, and Genentech, Inc. His last position at Genentech, Inc. was Vice President of Process Sciences. Dr. Lawlis serves on the boards of two public biopharmaceutical companies, Aeglea BioTherapeutics, Inc. and Geron Corporation. He previously served on the board of Sutro Biopharma, Inc., a public biopharmaceutical company, from January 2004 until June 2019. Dr. Lawlis holds board positions at two private companies, AbSci, LLC and Reform Biologics LLC, and he serves as an advisor to Phoenix Venture Partners, a venture capital firm focusing on manufacturing technologies and material sciences technologies. He also serves on the Manufacturing Advisory Board of Allakos, Inc. and he advises W.L. Gore and Associates. Dr. Lawlis holds a B.A. in microbiology from the University of Texas at Austin, and a Ph.D. in Biochemistry from Washington State University.
What is V. Bryan Lawlis' net worth?
The estimated net worth of V. Bryan Lawlis is at least $1.81 million as of April 3rd, 2023. Mr. Lawlis owns 28,950 shares of BioMarin Pharmaceutical stock worth more than $1,811,112 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. Lawlis may own. Learn More about V. Bryan Lawlis' net worth.
How do I contact V. Bryan Lawlis?
Has V. Bryan Lawlis been buying or selling shares of BioMarin Pharmaceutical?
V. Bryan Lawlis has not been actively trading shares of BioMarin Pharmaceutical within the last three months. Most recently, V Bryan Lawlis sold 8,500 shares of the business's stock in a transaction on Monday, April 3rd. The shares were sold at an average price of $97.09, for a transaction totalling $825,265.00. Following the completion of the sale, the director now directly owns 28,950 shares of the company's stock, valued at $2,810,755.50. Learn More on V. Bryan Lawlis' trading history.
Who are BioMarin Pharmaceutical's active insiders?
BioMarin Pharmaceutical's insider roster includes Jeffrey Ajer (EVP), Mark Alles (Director), Jean Bienaime (CEO), George Davis (EVP), Willard Dere (Director), Henry Fuchs (Insider), Michael Grey (Director), Charles Guyer (EVP), V. Lawlis (Director), Richard Meier (Director), Brian Mueller (CFO), David Pyott (Director), and Dennis Slamon (Director). Learn More on BioMarin Pharmaceutical's active insiders.
Are insiders buying or selling shares of BioMarin Pharmaceutical?
In the last twelve months, insiders at the biotechnology company sold shares 16 times. They sold a total of 209,971 shares worth more than $17,856,129.12. The most recent insider tranaction occured on November, 12th when EVP Charles Greg Guyer sold 5,278 shares worth more than $350,300.86. Insiders at BioMarin Pharmaceutical own 1.9% of the company.
Learn More about insider trades at BioMarin Pharmaceutical. Information on this page was last updated on 11/12/2024.